European Commission Searches for Committee Experts
The EC is calling for interested parties for their safety and orphan drug committees.
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
On Nov. 3, 2023, the European Commission announced it was launching a selection procedure for experts looking to join the European Medicines Agency’s (EMA’s) independent Pharmacovigilance Risk Assessment Committee (PRAC) and Committee for Orphan Medicinal Products (COMP). PRAC is looking for six appointees, and COMP is looking for three new members.
The six PRAC experts will be appointed to a three-year term that starts on July 2, 2024 and will have an active role in supervision of medicines in Europe. Members of PRAC are independent scientific experts and are expected to actively contribute to PRAC discussions.
COMP is looking for three new committee members to represent patients’ organizations for a three-year term that begins July 1, 2024. Members participate in COMP procedures and attend monthly meetings. They also contribute to scientific discussions, examine documents, and speak for their target group. COMP members are also members of EMA’s Pharmacovigilance Risk Assessment Committee, Paediatric Committee, and Committee for Advanced Therapies.
“The COMP has a strong tradition of involving patient representatives in its work. Its main task is to examine applications sent by companies and decide whether their medicines can be designated as 'orphan'. An orphan medicine is used in the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition that is rare, which means it affects no more than five in 10,000 people in the European Union (EU). The role of a patient organization representative in the COMP is to give a voice to patients and ensure their needs are taken into account in the Committee's decision-making process. Although a medical background is not required, candidates may benefit from a sound knowledge of medical and, to a certain extent, regulatory issues related to medicines in the EU,” the agency stated in a press release.
Submissions for applications for either commission are due Dec. 7, 2023 at 12:00 CET. Current members may also re-apply.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
